Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDRIX4-LUNG in Metastatic NSCLC
NCT04082182Phase 1Unknown
- Sponsor
- Ghent University Hospital
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MIDRIX4 in non-small cell lung cancer (NSCLC), sponsored by Ghent University Hospital. Primary endpoints: Toxicity as defined by common toxicity criteria v5.0 and Maximal tolerated dose. Status: unknown.
02
Drugs
MIDRIX4
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04082182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082182.